470.13
price up icon2.54%   11.64
pre-market  Pre-mercato:  470.78   0.65   +0.14%
loading
Precedente Chiudi:
$458.49
Aprire:
$461.03
Volume 24 ore:
1.00M
Relative Volume:
0.66
Capitalizzazione di mercato:
$120.73B
Reddito:
$11.10B
Utile/perdita netta:
$-988.90M
Rapporto P/E:
-119.93
EPS:
-3.92
Flusso di cassa netto:
$-1.26B
1 W Prestazione:
+1.28%
1M Prestazione:
+6.64%
6M Prestazione:
+9.84%
1 anno Prestazione:
-5.20%
Intervallo 1D:
Value
$458.88
$470.80
Intervallo di 1 settimana:
Value
$456.83
$472.22
Portata 52W:
Value
$377.85
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Nome
Vertex Pharmaceuticals Inc
Name
Telefono
(617) 341-6393
Name
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Name
Dipendente
6,100
Name
Cinguettio
@VertexPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
VRTX's Discussions on Twitter

Confronta VRTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-07 Downgrade Wolfe Research Outperform → Peer Perform
2025-05-06 Downgrade Leerink Partners Outperform → Market Perform
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-12 Aggiornamento Canaccord Genuity Sell → Hold
2025-02-11 Aggiornamento Canaccord Genuity Sell → Hold
2025-01-30 Downgrade Wells Fargo Overweight → Equal Weight
2024-12-20 Reiterato H.C. Wainwright Buy
2024-12-19 Downgrade Oppenheimer Outperform → Perform
2024-12-09 Aggiornamento Jefferies Hold → Buy
2024-11-14 Iniziato Citigroup Buy
2024-10-16 Iniziato Scotiabank Sector Perform
2024-10-10 Ripresa Raymond James Mkt Perform
2024-08-05 Downgrade Barclays Overweight → Equal Weight
2024-06-27 Iniziato Redburn Atlantic Buy
2024-04-11 Aggiornamento Evercore ISI In-line → Outperform
2024-02-15 Iniziato Wolfe Research Outperform
2024-02-06 Downgrade Evercore ISI Outperform → In-line
2024-02-02 Downgrade Bernstein Outperform → Mkt Perform
2024-01-31 Downgrade Maxim Group Buy → Hold
2024-01-31 Downgrade Robert W. Baird Neutral → Underperform
2024-01-24 Downgrade Canaccord Genuity Hold → Sell
2023-12-14 Reiterato RBC Capital Mkts Sector Perform
2023-05-30 Iniziato William Blair Outperform
2023-05-04 Ripresa Piper Sandler Overweight
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Hold
2023-01-17 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-12-19 Downgrade Jefferies Buy → Hold
2022-07-13 Iniziato Cantor Fitzgerald Overweight
2022-06-01 Aggiornamento Maxim Group Hold → Buy
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-05-06 Downgrade Robert W. Baird Outperform → Neutral
2022-05-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-02-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-01-27 Reiterato JP Morgan Overweight
2022-01-27 Reiterato Morgan Stanley Underweight
2022-01-27 Reiterato RBC Capital Mkts Outperform
2022-01-27 Reiterato Stifel Hold
2022-01-27 Reiterato Wolfe Research Outperform
2022-01-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-12-09 Iniziato Wells Fargo Overweight
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-19 Downgrade Piper Sandler Overweight → Neutral
2021-09-09 Downgrade Stifel Buy → Hold
2021-09-07 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-07-20 Downgrade SVB Leerink Mkt Perform → Underperform
2021-07-19 Ripresa Wolfe Research Outperform
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-11 Downgrade Daiwa Securities Outperform → Neutral
2021-02-23 Aggiornamento Robert W. Baird Neutral → Outperform
2021-02-02 Reiterato H.C. Wainwright Buy
2020-12-30 Iniziato Daiwa Securities Outperform
2020-11-30 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2020-11-20 Iniziato Bernstein Outperform
2020-10-28 Iniziato UBS Buy
2020-07-31 Reiterato H.C. Wainwright Buy
2020-07-08 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-04-30 Reiterato H.C. Wainwright Buy
2020-04-28 Downgrade RBC Capital Mkts Outperform → Sector Perform
2020-03-04 Iniziato Barclays Overweight
2020-01-31 Downgrade Robert W. Baird Outperform → Neutral
2019-11-19 Aggiornamento Guggenheim Neutral → Buy
2019-11-12 Iniziato SunTrust Buy
2019-10-17 Ripresa BofA/Merrill Buy
2019-09-03 Aggiornamento Goldman Neutral → Buy
2019-08-01 Downgrade Needham Buy → Hold
2019-05-23 Ripresa Citigroup Buy
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-12 Iniziato Evercore ISI In-line
2019-03-26 Aggiornamento William Blair Mkt Perform → Outperform
2019-03-19 Downgrade SVB Leerink Outperform → Mkt Perform
2019-02-06 Downgrade Maxim Group Buy → Hold
Mostra tutto

Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie

pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Chart Pattern Guide - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Vertex Pharmaceuticals Incorporated stock priceConsistent triple returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool

Jul 22, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com

Jul 21, 2025
pulisher
Jul 20, 2025

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive

Jul 15, 2025
pulisher
Jul 15, 2025

Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE

Jul 15, 2025
pulisher
Jul 15, 2025

NICE backs Vertex's cystic fibrosis triple combo Alyftrek - FirstWord Pharma

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

New cystic fibrosis triple from Vertex backed for NHS use - pharmaphorum

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals and NHS England Reach Agreement to Provide Alyftrek for Cystic Fibrosis Treatment - geneonline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

Vertex Pharmaceuticals' ALYFTREK® Approval: A Catalyst for EU Dominance and Revenue Growth? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

(Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire

Jul 14, 2025
pulisher
Jul 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX - Business Wire

Jul 14, 2025
pulisher
Jul 14, 2025

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Yahoo Finance

Jul 14, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha

Jul 13, 2025
pulisher
Jul 11, 2025

Small Fiber Neuropathy Market Growth Projections 2023-2032: DelveInsight Analysis | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark Pharma, Regency - Barchart.com

Jul 11, 2025
pulisher
Jul 10, 2025

Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek - Fierce Pharma

Jul 10, 2025
pulisher
Jul 09, 2025

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch (NASDAQ:VRTX) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE

Jul 09, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire

Jul 08, 2025
pulisher
Jul 08, 2025

Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Insider Monkey

Jul 08, 2025
pulisher
Jul 08, 2025

FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals to Announce Q2 2025 Earnings on August 4th - AInvest

Jul 08, 2025

Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$560.93
price up icon 2.82%
$325.28
price up icon 1.49%
$571.23
price up icon 0.90%
biotechnology ONC
$295.59
price up icon 1.25%
$111.44
price up icon 2.32%
Capitalizzazione:     |  Volume (24 ore):